SCHEMBL7659883

SCHEMBL7659883

Cc1ccc2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.71
TP53 P04637 8/20 0.71
CSNK2A2 P19784 7/20 0.71
CSNK2B P67870 7/20 0.71
CSNK2A1 P68400 7/20 0.71
KDM4E B2RXH2 6/20 0.71
MEN1 O00255 5/20 0.69
CYP3A4 P08684 5/20 0.69
KMT2A Q03164 5/20 0.69
ALDH1A1 P00352 3/20 0.69
CASP1 P29466 2/20 0.69
CASP7 P55210 2/20 0.69
CDK2 P24941 6/20 0.68
ALOX12 P18054 4/20 0.68
CYP2C9 P11712 4/20 0.68
HSD17B10 Q99714 4/20 0.68
ALOX15 P16050 3/20 0.68
MAPK1 P28482 3/20 0.68
RECQL P46063 3/20 0.68
CYP2D6 P10635 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12378689 0.89 MEN1 (0.75) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL6770344 0.88 MAPT (0.67) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL28457641 0.86 MAPT (0.71) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL12590664 0.86 MAPT (0.84) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL12590223 0.86 MAPT (0.84) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL505584 0.86 MEN1 (0.79) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL7657770 0.84 MEN1 (0.68) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL10037939 0.84 MEN1 (0.76) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL7655634 0.83 MEN1 (0.68) MAPTTP53CSNK2A2CSNK2BCSNK2A1
SCHEMBL7652737 0.83 MEN1 (0.68) MAPTTP53CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103929959-A Neuroprotective polyphenol analogs SALK INST FOR BIOLOGICAL STUDI 2014-07-16 CN claimed
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-07-03 US claimed
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2014-07-03 US claimed
EP-2741609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS Salk Institute for Biological Studies (US) 2014-06-18 EP claimed
WO-2013025484-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA LAPCHAK PAUL A (US) 2013-02-21 WO claimed
WO-2013025498-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SCHUBERT DAVID R (US) 2013-02-21 WO claimed
EP-1109800-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LIMITED (KR) 2001-06-27 EP claimed
WO-2000012496-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LTD. (KR) 2000-03-09 WO claimed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20090258939-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. 2009-10-15 US disclosed
WO-2009018350-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2009-02-05 WO disclosed
WO-2009018320-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2009-02-05 WO disclosed
US-6500846-B1 2-(4-CHLOROPHENYL)-7-METHOXYCHROMEN-4-ONE, AS CYCLIN-DEPENDENT KINASE INHIBITORS, USED AS ANTICARCINOGENIC AGENTS OR FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASE LG CHEMICAL, LTD. (KR) 2002-12-31 US disclosed
EP-1109800-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LIMITED (KR) 2001-06-27 EP disclosed
WO-2000012496-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LTD. (KR) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA GPX1, KEAP1, GPX4 MAPT 3438/4885TP53 1653/4885CSNK2A2 4845/4885
US-20090258939-A1 PYRONE ANALOG COMPOSITIONS AND METHODS CYP11B2, CYP11B1, GLS2 MAPT 2788/4885TP53 578/4885CSNK2A2 2956/4885
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC MAPT 68/4885TP53 721/4885CSNK2A2 4874/4885
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC MAPT 68/4885TP53 721/4885CSNK2A2 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.